ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional Results available

Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

ClinicalTrials.gov ID: NCT01638546

Public ClinicalTrials.gov record NCT01638546. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 12:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Center, Randomized, Double-Blind Phase II Study Comparing ABT-888, a PARP Inhibitor, Versus Placebo With Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer

Study identification

NCT ID
NCT01638546
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
National Cancer Institute (NCI)
NIH
Enrollment
97 participants

Conditions and interventions

Interventions

  • Laboratory Biomarker Analysis Other
  • Placebo Administration Other
  • Temozolomide Drug
  • Veliparib Drug

Other · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 26, 2012
Primary completion
Jan 8, 2017
Completion
Mar 24, 2027
Last update posted
Apr 28, 2026

2012 – 2027

United States locations

U.S. sites
14
U.S. states
10
U.S. cities
13
Facility City State ZIP Site status
Moffitt Cancer Center Tampa Florida 33612
Emory University Hospital/Winship Cancer Institute Atlanta Georgia 30322
Johns Hopkins Bayview Medical Center Baltimore Maryland 21224
Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore Maryland 21287
Washington University School of Medicine St Louis Missouri 63110
Memorial Sloan Kettering Basking Ridge Basking Ridge New Jersey 07920
Memorial Sloan Kettering Commack Commack New York 11725
Memorial Sloan Kettering Cancer Center New York New York 10065
Memorial Sloan Kettering Sleepy Hollow Sleepy Hollow New York 10591
Memorial Sloan Kettering Nassau Uniondale New York 11553
UNC Lineberger Comprehensive Cancer Center Chapel Hill North Carolina 27599
Case Western Reserve University Cleveland Ohio 44106
M D Anderson Cancer Center Houston Texas 77030
VCU Massey Comprehensive Cancer Center Richmond Virginia 23298

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01638546, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 28, 2026 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01638546 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →